The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Body composition parameter as risk predictor in metastatic renal cell carcinoma (mRCC)?
 
Constantin Heetfeld
No Relationships to Disclose
 
Bennet Hensen
No Relationships to Disclose
 
Hendik Eggers
Travel, Accommodations, Expenses - Ipsen
 
Inga Peters
No Relationships to Disclose
 
Markus A Kuczyk
No Relationships to Disclose
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; AstraZeneca; Bristol-Myers Squibb; ClinSol; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Debiopharm Group; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Onkowissen; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Pfizer
 
Philipp Ivanyi
Honoraria - AIM Specialty Health; Apogepha; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Florian Schmitz Communication; MedKom; Meet the Experts Academy; Merck Serono; MSD; New Concept Oncology; Pfizer; PharmaMar; Roche; Streamedup!
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; ClinSol; Deciphera; Eisai; EMD Serono; EUSA Pharma; Ipsen; Merck Serono; Metaplan; MSD; Onkowissen; Pfizer
Research Funding - AstraZeneca (I); Bristol-Myers Squibb (Inst); Eisai (Inst); EUSA Pharma (Inst); Ipsen (Inst); MSD (Inst)